NCT07216391View on ClinicalTrials.gov

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Antithymocyte Globulin (ATG)

Thymoglobulin

DRUG

Teplizumab

Intravenous infusions of teplizumab given for 14 consecutive days. Each infusion takes about 30 minutes and is followed by an observation period of at least 30 minutes.

Trial Locations (1)

32610

University of Florida, Gainesville

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH